港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

宜明昂科-B

11.800

-0.530-4.30%

成交量：174.54萬

成交額：2,057.75萬

市值：48.06億

市盈率：-12.93

高：12.400

開：12.340

低：11.610

收：12.330

52周最高：15.660

52周最低：3.210

股本：4.07億

香港流通股本：3.96億

量比：0.73

換手率：0.44%

股息：- -

股息率：- -

每股收益(LYR):-0.913

淨資產收益率：-44.38%

總資產收益率：-21.43%

市淨率：6.50

市盈率(LYR):-12.93

市銷率: 55.46

資料載入中...

總覽公司新聞公告

不在港股通股價也狂飆，PD-(L)1/VEGF雙抗熱潮下，宜明昂科有“幾把刷子”？

医药研究社

宜明昂科-B盤中異動早盤快速跳水5.10%

宜明昂科：於無聲處聽驚雷

宜明昂科-B再漲超13% IMM01、IMM2510等研究成果將在ASCO年會亮相

宜明昂科-B盤中異動早盤急速上漲5.28%

港股異動 | 醫藥股再度走高國產創新藥迎多重利好共振機構稱數據和BD催化有望成全年主線

港股異動 | 宜明昂科-B漲超18%，月內股價累漲超110%

智通财经网

宜明昂科-B05月29日獲主力加倉113.9萬元

宜明昂科-B(01541)：張如亮獲委任為執行董事

宜明昂科-B05月28日獲主力加倉31.2萬元

港股異動 | 宜明昂科-B(01541)再漲超5% 月內累漲近80% 與Instil Bio臨牀合作開發持續推進

宜明昂科-B05月27日主力淨流入490.1萬元散戶資金拋售

港股異動 | 宜明昂科-B(01541)逆勢漲超3% IMM2510聯合化療2期試驗結果預計下半年公佈

宜明昂科-B盤中異動早盤股價大漲5.05%報9.990港元

冷卻的CD47靶點：黃金礦，還是沼澤地？ | 海斌訪談

宜明昂科-B：2025 年多項試驗新進展雙抗亮眼

宜明昂科-B高開近10% 預計下半年公佈IMM2510聯合化療2期試驗結果

異動解讀 | 宜明昂科-B盤中大漲9.73%，IMM2510/AXN-2510臨牀試驗進展利好

異動解讀 | 宜明昂科-B盤中大漲9.73%，新藥臨牀試驗進展良好

港股異動 | 宜明昂科-B(01541)高開近10% IMM2510聯合化療2期試驗結果預計下半年公佈

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01541/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01541","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":11.8,"timestamp":1756195699002,"preClose":12.33,"halted":0,"volume":1745400,"delay":0,"floatShares":396277305,"shares":407307695,"eps":-0.9125256220642456,"marketStatus":"未開盤","change":-0.53,"latestTime":"08-26 16:08:19","open":12.34,"high":12.4,"low":11.61,"amount":20577460,"amplitude":0.064071,"askPrice":11.8,"askSize":200,"bidPrice":11.75,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.9125256220642456,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1756258200000},"marketStatusCode":0,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":12.33,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.726778,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","floatShares":396277305,"roa":"-21.43%","roe":"-44.38%","lyrEps":-0.912526,"volumeRatio":0.726778,"shares":407307695,"dividePrice":0,"high":12.4,"amplitude":0.064071,"preClose":12.33,"low":11.61,"week52Low":3.21,"pbRate":"6.50","psRate":"55.46","week52High":15.66,"institutionHeld":0,"latestPrice":11.8,"committee":0.818182,"eps":-0.9125256220642456,"divideRate":0,"volume":1745400,"delay":0,"ttmEps":-0.9125256220642456,"open":12.34,"prevYearClose":5.16,"prevWeekClose":12.02,"prevMonthClose":11.02,"prevQuarterClose":12,"fiveDayClose":12.96,"twentyDayClose":11.76,"sixtyDayClose":14.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01541\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null},{"date":"2025-03-25","symbol":"01541","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742866200000,"name":null,"time":"盤後","dateTimestamp":1742832000000,"actualEps":null},{"market":"HK","date":"2024-08-26","symbol":"01541","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1724601600000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01541\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01541\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1697558400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01541\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01541","date":"2025-08-25","current":-14.555161,"percent":0.328542,"low":-30.003263,"twenty":-22.665631,"median":-13.01303,"eighty":-6.054191,"high":-2.993766,"avg":-13.617797,"sd":7.665432,"marketCap":5022103879},"quantilePoints":[{"date":"2023-08-31","current":-17.746094,"twenty":-17.746094,"median":-17.746094,"eighty":-17.746094,"marketCap":6942262047},{"date":"2023-09-08","current":-19.116691,"twenty":-19.083294,"median":-18.655615,"eighty":-17.801139,"marketCap":7390149921},{"date":"2023-09-15","current":-24.765877,"twenty":-24.765877,"median":-19.116691,"eighty":-18.557812,"marketCap":9648251285},{"date":"2023-09-22","current":-25.548224,"twenty":-25.200205,"median":-24.360534,"eighty":-18.753419,"marketCap":9909519212},{"date":"2023-09-29","current":-29.804324,"twenty":-26.447668,"median":-24.870232,"eighty":-19.083294,"marketCap":11580180660},{"date":"2023-10-06","current":-24.76052,"twenty":-26.458287,"median":-24.870232,"eighty":-19.110012,"marketCap":9615852761},{"date":"2023-10-13","current":-27.113287,"twenty":-26.458287,"median":-25.206314,"eighty":-22.322253,"marketCap":10513831229},{"date":"2023-10-20","current":-26.768577,"twenty":-26.795293,"median":-25.37532,"eighty":-23.788881,"marketCap":10364168151},{"date":"2023-10-27","current":-28.665306,"twenty":-27.124745,"median":-25.753577,"eighty":-24.00727,"marketCap":11093775656},{"date":"2023-11-03","current":-26.275244,"twenty":-27.500238,"median":-26.158488,"eighty":-24.473108,"marketCap":10195797188},{"date":"2023-11-10","current":-26.039628,"twenty":-27.37617,"median":-26.041732,"eighty":-24.763734,"marketCap":10102257765},{"date":"2023-11-17","current":-26.714897,"twenty":-27.225983,"median":-26.171076,"eighty":-24.792429,"marketCap":10457707575},{"date":"2023-11-24","current":-27.539565,"twenty":-27.37617,"median":-26.271304,"eighty":-24.846191,"marketCap":10869281039},{"date":"2023-12-01","current":-28.464343,"twenty":-27.564693,"median":-26.306056,"eighty":-24.874164,"marketCap":11280854504},{"date":"2023-12-08","current":-27.67933,"twenty":-27.70336,"median":-26.447668,"eighty":-25.070837,"marketCap":10925404694},{"date":"2023-12-15","current":-27.708906,"twenty":-27.817253,"median":-26.526325,"eighty":-25.207536,"marketCap":11000236233},{"date":"2023-12-22","current":-27.916049,"twenty":-27.937914,"median":-26.714897,"eighty":-25.244891,"marketCap":11075067772},{"date":"2023-12-29","current":-28.049426,"twenty":-27.986303,"median":-26.835368,"eighty":-25.288293,"marketCap":11187315080},{"date":"2024-01-05","current":-23.146888,"twenty":-27.970711,"median":-26.68937,"eighty":-25.200205,"marketCap":9166863527},{"date":"2024-01-12","current":-26.439512,"twenty":-27.935571,"median":-26.500765,"eighty":-25.200205,"marketCap":10476415460},{"date":"2024-01-19","current":-25.435754,"twenty":-27.916049,"median":-26.490281,"eighty":-25.212424,"marketCap":10064841995},{"date":"2024-01-26","current":-23.636611,"twenty":-27.83997,"median":-26.442842,"eighty":-24.972615,"marketCap":9316526605},{"date":"2024-02-02","current":-21.195554,"twenty":-27.817533,"median":-26.372788,"eighty":-24.783518,"marketCap":8343716598},{"date":"2024-02-09","current":-18.727145,"twenty":-27.802108,"median":-26.275244,"eighty":-24.041989,"marketCap":7408322361},{"date":"2024-02-16","current":-17.739662,"twenty":-27.801452,"median":-26.252628,"eighty":-23.794995,"marketCap":7019198358},{"date":"2024-02-23","current":-22.387155,"twenty":-27.764049,"median":-26.165159,"eighty":-23.13759,"marketCap":8811413717},{"date":"2024-03-01","current":-17.708555,"twenty":-27.735275,"median":-26.04068,"eighty":-22.460898,"marketCap":6974299434},{"date":"2024-03-08","current":-19.229551,"twenty":-27.718352,"median":-26.025076,"eighty":-21.141323,"marketCap":7576693323},{"date":"2024-03-15","current":-16.157629,"twenty":-27.69116,"median":-25.695795,"eighty":-19.998834,"marketCap":6360680815},{"date":"2024-03-22","current":-15.411367,"twenty":-27.66021,"median":-25.548224,"eighty":-19.057216,"marketCap":6061354659},{"date":"2024-03-28","current":-14.696214,"twenty":-27.629432,"median":-25.408294,"eighty":-18.737655,"marketCap":6038905197},{"date":"2024-04-05","current":-13.011166,"twenty":-27.602384,"median":-25.364375,"eighty":-18.557812,"marketCap":5342971884},{"date":"2024-04-12","current":-13.094845,"twenty":-27.539565,"median":-25.225009,"eighty":-18.239836,"marketCap":5380387654},{"date":"2024-04-19","current":-13.014894,"twenty":-27.51439,"median":-25.154554,"eighty":-17.708555,"marketCap":5342971884},{"date":"2024-04-26","current":-13.779237,"twenty":-27.443648,"median":-24.972615,"eighty":-16.602696,"marketCap":5649781194},{"date":"2024-05-03","current":-12.839078,"twenty":-27.434442,"median":-24.870232,"eighty":-16.184677,"marketCap":5260657191},{"date":"2024-05-10","current":-13.282389,"twenty":-27.357513,"median":-24.774698,"eighty":-14.702373,"marketCap":5455219193},{"date":"2024-05-17","current":-13.228926,"twenty":-27.225983,"median":-24.581805,"eighty":-14.243189,"marketCap":5425286577},{"date":"2024-05-24","current":-13.350651,"twenty":-27.145452,"median":-23.955191,"eighty":-13.966896,"marketCap":5462702347},{"date":"2024-05-31","current":-13.410156,"twenty":-27.124745,"median":-23.750163,"eighty":-13.747349,"marketCap":5492634962},{"date":"2024-06-07","current":-14.158514,"twenty":-27.039336,"median":-23.288627,"eighty":-13.645876,"marketCap":5791961118},{"date":"2024-06-14","current":-13.347574,"twenty":-26.971042,"median":-23.123643,"eighty":-13.527845,"marketCap":5455219193},{"date":"2024-06-21","current":-13.283836,"twenty":-26.926395,"median":-22.448608,"eighty":-13.452996,"marketCap":5417803423},{"date":"2024-06-28","current":-12.683619,"twenty":-26.848726,"median":-21.974147,"eighty":-13.40419,"marketCap":5170859344},{"date":"2024-07-05","current":-11.291057,"twenty":-26.759122,"median":-21.059976,"eighty":-13.359292,"marketCap":4602139648},{"date":"2024-07-12","current":-12.246119,"twenty":-26.720023,"median":-20.206581,"eighty":-13.323498,"marketCap":4998746805},{"date":"2024-07-19","current":-11.915911,"twenty":-26.704686,"median":-19.229551,"eighty":-13.282563,"marketCap":4864050035},{"date":"2024-07-26","current":-11.780484,"twenty":-26.652155,"median":-19.050696,"eighty":-13.224977,"marketCap":4826634265},{"date":"2024-08-02","current":-13.633124,"twenty":-26.594701,"median":-18.753419,"eighty":-13.20236,"marketCap":5582432809},{"date":"2024-08-09","current":-9.567144,"twenty":-26.54166,"median":-18.630761,"eighty":-13.102374,"marketCap":3943622105},{"date":"2024-08-16","current":-8.483685,"twenty":-26.496571,"median":-18.451463,"eighty":-13.086665,"marketCap":3498374448},{"date":"2024-08-23","current":-8.095604,"twenty":-26.47337,"median":-18.020488,"eighty":-13.035717,"marketCap":3352452947},{"date":"2024-08-30","current":-7.377309,"twenty":-26.446703,"median":-17.739662,"eighty":-12.990136,"marketCap":3034418906},{"date":"2024-09-06","current":-4.227864,"twenty":-26.442176,"median":-17.681919,"eighty":-12.840212,"marketCap":1739833281},{"date":"2024-09-13","current":-4.503325,"twenty":-26.43833,"median":-16.602696,"eighty":-12.741292,"marketCap":1848339013},{"date":"2024-09-20","current":-4.539912,"twenty":-26.433601,"median":-16.202037,"eighty":-12.246119,"marketCap":1874530051},{"date":"2024-09-27","current":-5.476578,"twenty":-26.311976,"median":-15.844451,"eighty":-11.915911,"marketCap":2274878785},{"date":"2024-10-04","current":-6.596451,"twenty":-26.302504,"median":-15.05764,"eighty":-11.832338,"marketCap":2727609596},{"date":"2024-10-10","current":-5.983695,"twenty":-26.285201,"median":-14.496802,"eighty":-11.807116,"marketCap":2458216056},{"date":"2024-10-18","current":-5.191078,"twenty":-26.27288,"median":-14.209972,"eighty":-11.719903,"marketCap":2121474130},{"date":"2024-10-25","current":-7.104995,"twenty":-26.248892,"median":-14.119017,"eighty":-11.287262,"marketCap":2903463713},{"date":"2024-11-01","current":-6.615271,"twenty":-26.199776,"median":-13.881638,"eighty":-9.764235,"marketCap":2705160134},{"date":"2024-11-08","current":-6.847628,"twenty":-26.169892,"median":-13.803075,"eighty":-8.441853,"marketCap":2787474827},{"date":"2024-11-15","current":-7.078843,"twenty":-26.118271,"median":-13.690467,"eighty":-8.248986,"marketCap":2851081635},{"date":"2024-11-22","current":-6.784782,"twenty":-26.059844,"median":-13.633178,"eighty":-7.853303,"marketCap":2731351173},{"date":"2024-11-29","current":-5.682581,"twenty":-26.04047,"median":-13.539989,"eighty":-7.45767,"marketCap":2286103516},{"date":"2024-12-06","current":-5.602773,"twenty":-26.037499,"median":-13.514674,"eighty":-7.358253,"marketCap":2248687746},{"date":"2024-12-13","current":-6.121403,"twenty":-26.029477,"median":-13.45004,"eighty":-7.218028,"marketCap":2451992323},{"date":"2024-12-20","current":-5.137492,"twenty":-25.962318,"median":-13.411134,"eighty":-7.087735,"marketCap":2048757705},{"date":"2024-12-27","current":-4.957491,"twenty":-25.887099,"median":-13.400213,"eighty":-7.078006,"marketCap":1975442320},{"date":"2025-01-03","current":-5.238569,"twenty":-25.753577,"median":-13.368079,"eighty":-6.925822,"marketCap":2089488475},{"date":"2025-01-10","current":-5.002231,"twenty":-25.638014,"median":-13.3526,"eighty":-6.765934,"marketCap":1987661551},{"date":"2025-01-17","current":-5.018682,"twenty":-25.5579,"median":-13.317479,"eighty":-6.665777,"marketCap":1995807705},{"date":"2025-01-24","current":-5.323319,"twenty":-25.548224,"median":-13.283546,"eighty":-6.596451,"marketCap":2130219244},{"date":"2025-01-28","current":-5.224689,"twenty":-25.503236,"median":-13.282823,"eighty":-6.532117,"marketCap":2101707706},{"date":"2025-02-07","current":-5.549725,"twenty":-25.42477,"median":-13.246663,"eighty":-6.254752,"marketCap":2219826937},{"date":"2025-02-14","current":-5.930475,"twenty":-25.395104,"median":-13.220128,"eighty":-6.076947,"marketCap":2366457707},{"date":"2025-02-21","current":-6.375256,"twenty":-25.366564,"median":-13.201126,"eighty":-6.054191,"marketCap":2557892324},{"date":"2025-02-28","current":-5.632443,"twenty":-25.318672,"median":-13.116805,"eighty":-5.974648,"marketCap":2252411553},{"date":"2025-03-07","current":-5.782376,"twenty":-25.249925,"median":-13.099044,"eighty":-5.827424,"marketCap":2321653861},{"date":"2025-03-14","current":-4.421401,"twenty":-25.219975,"median":-13.087912,"eighty":-5.725677,"marketCap":1775861550},{"date":"2025-03-21","current":-4.778207,"twenty":-25.207536,"median":-13.071662,"eighty":-5.66584,"marketCap":1918419243},{"date":"2025-03-28","current":-6.735516,"twenty":-25.163684,"median":-13.026305,"eighty":-5.651503,"marketCap":2276850015},{"date":"2025-04-03","current":-7.956153,"twenty":-25.0977,"median":-13.01303,"eighty":-5.66026,"marketCap":2684157710},{"date":"2025-04-11","current":-6.344288,"twenty":-25.036833,"median":-12.972072,"eighty":-5.68428,"marketCap":2126146167},{"date":"2025-04-17","current":-6.122985,"twenty":-24.972615,"median":-12.844749,"eighty":-5.691075,"marketCap":2056903859},{"date":"2025-04-25","current":-8.576896,"twenty":-24.895951,"median":-12.836736,"eighty":-5.703559,"marketCap":2883738480},{"date":"2025-05-02","current":-7.700417,"twenty":-24.872853,"median":-12.82514,"eighty":-5.710649,"marketCap":2594550017},{"date":"2025-05-09","current":-7.730765,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"marketCap":2623061555},{"date":"2025-05-16","current":-8.311097,"twenty":-24.799485,"median":-12.12195,"eighty":-5.751942,"marketCap":2843007711},{"date":"2025-05-23","current":-11.289802,"twenty":-24.776462,"median":-11.940532,"eighty":-5.771038,"marketCap":3873496179},{"date":"2025-05-30","current":-15.223569,"twenty":-24.763734,"median":-11.970101,"eighty":-5.797425,"marketCap":5246123111},{"date":"2025-06-06","current":-16.623143,"twenty":-24.617548,"median":-12.331836,"eighty":-5.827424,"marketCap":5743038499},{"date":"2025-06-13","current":-15.603079,"twenty":-24.258649,"median":-12.701975,"eighty":-5.862056,"marketCap":5392753881},{"date":"2025-06-20","current":-14.878015,"twenty":-24.00727,"median":-12.82804,"eighty":-5.90109,"marketCap":5132076957},{"date":"2025-06-27","current":-13.023121,"twenty":-23.933348,"median":-12.837907,"eighty":-5.91626,"marketCap":4504823106},{"date":"2025-07-04","current":-14.906416,"twenty":-23.89321,"median":-12.895238,"eighty":-5.935244,"marketCap":5156515418},{"date":"2025-07-11","current":-12.022018,"twenty":-23.818294,"median":-12.972072,"eighty":-5.957179,"marketCap":4154538489},{"date":"2025-07-18","current":-12.975089,"twenty":-23.597552,"median":-12.895238,"eighty":-5.971632,"marketCap":4480384645},{"date":"2025-07-25","current":-12.316929,"twenty":-23.410778,"median":-12.839078,"eighty":-5.984465,"marketCap":4268584643},{"date":"2025-08-01","current":-12.109688,"twenty":-23.260279,"median":-12.895238,"eighty":-5.992729,"marketCap":4170830796},{"date":"2025-08-08","current":-13.046774,"twenty":-23.142239,"median":-12.972072,"eighty":-6.013995,"marketCap":4504823106},{"date":"2025-08-15","current":-15.594562,"twenty":-23.052783,"median":-12.982136,"eighty":-6.023266,"marketCap":5376461574},{"date":"2025-08-22","current":-14.245172,"twenty":-22.717488,"median":-13.011166,"eighty":-6.052989,"marketCap":4895838493},{"date":"2025-08-25","current":-14.555161,"twenty":-22.665631,"median":-13.01303,"eighty":-6.054191,"marketCap":5022103879}],"updateTime":1756219202419},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01541\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540806930","title":"不在港股通股價也狂飆，PD-(L)1/VEGF雙抗熱潮下，宜明昂科有“幾把刷子”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2540806930","media":"医药研究社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540806930?lang=zh_tw&edition=fundamental","pubTime":"2025-06-04 20:46","pubTimestamp":1749041163,"startTime":"0","endTime":"0","summary":"目前，IMM2510这款PD-L1/VEGF双抗产品有很大希望成为宜明昂科的“印钞机”。当然，就现阶段而言，创新药开发门槛颇高，PD-1/VEGF双抗领域的“拉锯战”也已经开启，宜明昂科实现产品价值充分兑现不是容易的事。截至2024年12月31日，宜明昂科已收取首付款及近期付款1500万美元。好消息是，除了PD-1/VEGF双抗，宜明昂科手头还有不少热门产品管线。据宜明昂科介绍，凭借差异化的分子设计，IMM01已表现出良好的安全性并证实其激活巨噬细胞的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604205414a6fa4c6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604205414a6fa4c6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","BK1161","HSCEI","07226","01541"],"gpt_icon":0},{"id":"2540353084","title":"宜明昂科-B盤中異動 早盤快速跳水5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540353084","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540353084?lang=zh_tw&edition=fundamental","pubTime":"2025-06-04 09:44","pubTimestamp":1749001483,"startTime":"0","endTime":"0","summary":"2025年06月04日早盘09时44分，宜明昂科-B股票出现异动，股价快速下挫5.10%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。宜明昂科-B股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，中国抗体-B、君实生物、再鼎医药涨幅较大，振幅较大的相关个股有中国抗体-B、北海康成-B、宜明昂科-B，振幅分别为34.50%、13.75%、7.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604094443950dbc16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604094443950dbc16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2540576300","title":"宜明昂科：於無聲處聽驚雷","url":"https://stock-news.laohu8.com/highlight/detail?id=2540576300","media":"Jo的随笔","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540576300?lang=zh_tw&edition=fundamental","pubTime":"2025-06-02 15:53","pubTimestamp":1748850837,"startTime":"0","endTime":"0","summary":"对于市值仅为 59 亿港元左右的宜明昂科而言，IMM2510 这一条研发管线无疑成为了其稳健发展的关键支柱，意义重大。国产 PD-1/VEGF Vs. PD-L1/VEGF 研发竞争激烈PD-L1/VEGF 双抗阵营  宜明昂科 / Instil Bio 的 IMM2510：除了 ASCO 公布的数据外，IMM2510 凭借差异化设计和出色临床表现，在国际市场备受青睐。依沃西单抗于 2024 年 5 月获中国 NMPA 批准上市，同年 11 月被纳入国家医保目录。2022 年 12 月，康方生物将依沃西单抗海外权益授予 Summit，获得 5 亿美元首付款及最高 50 亿美元总交易金额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602155551a4965f48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602155551a4965f48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","IE00B5MMRT66.SGD","BK1161","LU0417516571.SGD","BK1574","LU0348783233.USD","LU0348784397.USD","09926","IE00BPRC5H50.USD","LU1794554557.SGD","01541","LU1720050803.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2540763006","title":"宜明昂科-B再漲超13% IMM01、IMM2510等研究成果將在ASCO年會亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2540763006","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540763006?lang=zh_tw&edition=fundamental","pubTime":"2025-06-02 15:41","pubTimestamp":1748850069,"startTime":"0","endTime":"0","summary":"宜明昂科-b再涨超13%，截至发稿，涨9.78%，报14.14港元，成交额8149.02万港元。值得注意的是，5月22日，宜明昂科的合作伙伴instil bio披露了PD-1xVEGF双抗AXN-2510的最新临床数据，受临床数据的影响，InsTIL Bio的股票一度高涨62%。开源证券指出，PD-1/VEGF双抗作为有望迭代PD-1单抗市场的下一代IO基石药物，后续与ADC/TCE等联用将持续拓宽市场空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602154442a4965c93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602154442a4965c93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2540751158","title":"宜明昂科-B盤中異動 早盤急速上漲5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540751158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540751158?lang=zh_tw&edition=fundamental","pubTime":"2025-06-02 10:47","pubTimestamp":1748832472,"startTime":"0","endTime":"0","summary":"2025年06月02日早盘10时47分，宜明昂科-B股票出现异动，股价快速拉升5.28%。宜明昂科-B股票所在的生物技术行业中，整体跌幅为2.97%。其相关个股中，北海康成-B、中国抗体-B、宜明昂科-B涨幅较大，振幅较大的相关个股有北海康成-B、中国抗体-B、嘉和生物-B，振幅分别为18.38%、14.86%、13.75%。宜明昂科-B公司简介：宜明昂科生物医药技术(上海)股份有限公司是一家主要从事测试生物技术研发的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602104752950b1326&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602104752950b1326&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2539113412","title":"港股異動 | 醫藥股再度走高 國產創新藥迎多重利好共振 機構稱數據和BD催化有望成全年主線","url":"https://stock-news.laohu8.com/highlight/detail?id=2539113412","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539113412?lang=zh_tw&edition=fundamental","pubTime":"2025-05-30 11:36","pubTimestamp":1748576198,"startTime":"0","endTime":"0","summary":"数据显示，数据显示，2025年第一季度，中国创新药license-out交易已有41起，总金额达369.29亿美元，仅3个月已接近2023年全年水平。今年ASCO年会上，中国研究者共计70余项原创研究入选口头报告。太平洋证券表示，流动性和风险偏好提升，数据和BD催化有望成为全年主线。交银国际研报指出，ASCO大会召开在即，LBA重磅数据即将揭晓，创新药板块有望迎来关注热潮、并有望在未来推动更多出海交易达成，市场情绪与板块估值将进入正向修复通道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8a007331050a4c5abbca4a26fc55f3d6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1299523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","159992","BK1161","BK1574","159938","02142","01672","03681","06127","BK1141","BK1515","BK1576","06978","BK1583","09939"],"gpt_icon":0},{"id":"2539216972","title":"港股異動 | 宜明昂科-B漲超18%，月內股價累漲超110%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539216972","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539216972?lang=zh_tw&edition=fundamental","pubTime":"2025-05-30 10:55","pubTimestamp":1748573721,"startTime":"0","endTime":"0","summary":"5月30日，$宜明昂科-B$盘中涨超18%，月内股价累涨超110%。消息面上，5月22日，宜明昂科公布IMM2510中国I/II期单药治疗NSCLC等实体瘤的有效性（13例）及安全性数据。宜明昂科已于2024年12月开展针对一线驱动基因阴性NSCLC和TNBC的中国II期临床，将于2025H2公布超过60例一线NSCLC患者经的初步安全性和有效性结果。据悉，IMM2510/AXN-2510是一种PD-L1和VEGF的双特异性抗体，目前正开发用于治疗多种实体肿瘤癌症。目前PD-1/VEGF双抗赛道景气度不断提高，相关标的有望持续受益。","market":"hk","thumbnail":"https://static.tigerbbs.com/a82005fdd5a20870413111b3adc1a547","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a82005fdd5a20870413111b3adc1a547"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1e124ae4aa8ace395ffe6e46863b90f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1299508.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4107","LU1169589451.USD","LU1169590202.USD","BK4585","LU0053666078.USD","BK4023","BK4588","01541","BK1161"],"gpt_icon":0},{"id":"2539253450","title":"宜明昂科-B05月29日獲主力加倉113.9萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539253450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539253450?lang=zh_tw&edition=fundamental","pubTime":"2025-05-29 16:15","pubTimestamp":1748506551,"startTime":"0","endTime":"0","summary":"05月29日, 宜明昂科-B股价涨5.17%，报收11.40元，成交金额5499.1万元，换手率1.22%，振幅7.38%，量比0.44。宜明昂科-B今日主力资金净流入113.9万元，连续3日净流入，上一交易日主力净流入31.2万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为70.00%，平均涨幅为9.15%。该股近5个交易日上涨18.01%，主力资金累计净流入1257.5万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4815.3万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529172915a4911bfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529172915a4911bfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2538424926","title":"宜明昂科-B(01541)：張如亮獲委任為執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2538424926","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538424926?lang=zh_tw&edition=fundamental","pubTime":"2025-05-28 17:51","pubTimestamp":1748425866,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，股东于股东周年大会批准后，张如亮先生获委任为第二届董事会执行董事及付大伟女士获委任为第二届董事会非执行董事。张先生及付女士的任期将由2025年5月28日起开始，直至第二届董事会任期届满时止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2538429765","title":"宜明昂科-B05月28日獲主力加倉31.2萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538429765","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538429765?lang=zh_tw&edition=fundamental","pubTime":"2025-05-28 16:15","pubTimestamp":1748420143,"startTime":"0","endTime":"0","summary":"05月28日, 宜明昂科-B股价涨2.26%，报收10.84元，成交金额9773.0万元，换手率2.26%，振幅10.19%，量比0.87。宜明昂科-B今日主力资金净流入31.2万元，上一交易日主力净流入490.1万元。该股近5个交易日上涨32.20%，主力资金累计净流入3384.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4678.9万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528172916a6f02402&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528172916a6f02402&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2538414603","title":"港股異動 | 宜明昂科-B(01541)再漲超5% 月內累漲近80% 與Instil Bio臨牀合作開發持續推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2538414603","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538414603?lang=zh_tw&edition=fundamental","pubTime":"2025-05-28 10:14","pubTimestamp":1748398449,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B再涨超5%，月内累计涨幅已近80%，截至发稿，涨2.64%，报10.88港元，成交额2021.22万港元。消息面上，宜明昂科近日公布，连同Instil Bio, Inc.宣布IMM2510/AXN-2510的临床最新情况及未来计划。值得注意的是，5月7日，宜明昂科宣布，就其2024年8月1日与Instil Bio, Inc对IMM2510及IMM27M达成的授权及合作，鉴于临床合作开发的顺利且快速的推进，已如期收到第二笔近期付款500万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541","BK4139","BK4505","TIL"],"gpt_icon":0},{"id":"2538574344","title":"宜明昂科-B05月27日主力淨流入490.1萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2538574344","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538574344?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 16:15","pubTimestamp":1748333738,"startTime":"0","endTime":"0","summary":"05月27日, 宜明昂科-B股价涨7.07%，报收10.60元，成交金额8837.5万元，换手率2.14%，振幅8.28%，量比0.80。宜明昂科-B今日主力资金净流入490.1万元，上一交易日主力净流出15.9万元。该股近5个交易日上涨41.15%，主力资金累计净流入4317.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4673.0万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527172513a6eeb08f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527172513a6eeb08f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2538127628","title":"港股異動 | 宜明昂科-B(01541)逆勢漲超3% IMM2510聯合化療2期試驗結果預計下半年公佈","url":"https://stock-news.laohu8.com/highlight/detail?id=2538127628","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538127628?lang=zh_tw&edition=fundamental","pubTime":"2025-05-26 15:15","pubTimestamp":1748243727,"startTime":"0","endTime":"0","summary":"消息面上，近日，宜明昂科和 Instil Bio, Inc.共同发布IMM2510/AXN-2510临床试验更新以及非小细胞肺癌临床开发战略。宜明昂科预计将于2025年年底完成IMM2510联合化疗治疗一线非小细胞肺癌患者的II期临床试验入组，第三季度完成约60名患者入组工作。宜明昂科预计将在2025年下半年分享该II期临床试验的初步安全性和有效性结果。竞争格局良好，目前只有宜明昂科及康方生物进行CD47靶点的研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1297470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2538142703","title":"宜明昂科-B盤中異動 早盤股價大漲5.05%報9.990港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538142703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538142703?lang=zh_tw&edition=fundamental","pubTime":"2025-05-26 09:39","pubTimestamp":1748223547,"startTime":"0","endTime":"0","summary":"2025年05月26日早盘09时39分，宜明昂科-B股票出现波动，股价大幅拉升5.05%。截至发稿，该股报9.990港元/股，成交量37.42万股，换手率0.09%，振幅5.68%。资金方面，该股资金流入209.15万港元，流出80.3536万港元。宜明昂科-B股票所在的生物技术行业中，整体涨幅为0.13%。其相关个股中，昭衍新药、宜明昂科-B、云康集团涨幅较大，振幅较大的相关个股有歌礼制药-B、巨子生物、瑞科生物-B，振幅分别为6.99%、6.71%、5.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052609390797655d73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052609390797655d73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2537195921","title":"冷卻的CD47靶點：黃金礦，還是沼澤地？ | 海斌訪談","url":"https://stock-news.laohu8.com/highlight/detail?id=2537195921","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537195921?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 19:11","pubTimestamp":1748085093,"startTime":"0","endTime":"0","summary":"“CD47这个金矿，前几年全球范围内很多公司都在挖，但最后感觉像是陷入了沼泽。”宜明昂科（01541.HK）董事长田文志近期表示。2020年左右，全球药企对CD47靶点趋之若鹜，将其视之为下一个PD-1。跨国药企吉利德、辉瑞等都为之投资巨大，中国至少二十家企业拿到临床批文。但全球药企巨额投资之后，纷纷偃旗息鼓，CD47靶点还没有诞生一颗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505243413689166.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505243413689166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1929549753.HKD","09926","IE00BLSP4452.SGD","LU2112291526.USD","LU0868494617.USD","LU0348784397.USD","SG9999014575.USD","IE0002141913.USD","SGXZ57979304.SGD","LU2488822045.USD","IE00BFTCPJ56.SGD","LU2023250843.SGD","MRK","LU1057294990.SGD","LU1066051811.HKD","LU0320765489.SGD","LU1037948541.HKD","BK1161","IE00B19Z3581.USD","LU0053666078.USD","BK4581","LU1585245621.USD","01541","SG9999013999.USD","IE00B2B36J28.USD","LU1162221912.USD","LU0058720904.USD","LU0417516571.SGD","L","LU1883839398.USD","SG9999002224.SGD","LU1894683348.USD","BK4588","LU0985481810.HKD","IE00BBT3K403.USD","LU1941712264.USD","BK4007","LU2023250504.SGD","LU0225771236.USD","BK1574","LU1430594728.SGD","LU0306807586.USD","LU2106854487.HKD","IE00B1BXHZ80.USD","LU1934455277.USD","LU2461242641.AUD","BK4533","LU1941712348.USD","LU0170899867.USD"],"gpt_icon":1},{"id":"2537977701","title":"宜明昂科-B：2025 年多項試驗新進展 雙抗亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2537977701","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537977701?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 10:12","pubTimestamp":1747966365,"startTime":"0","endTime":"0","summary":"5 月 22 日，宜明昂科和 InstilBio，Inc．共同发布 IMM2510/AXN-2510 临床试验更新以及非小细胞肺癌临床开发战略宜明昂科预计将于 2025 年年底完成 IMM2510 联合化疗治疗一线非小细胞肺癌患者的 II 期临床试验入组，第三季度完成约 60 名患者入组工作宜明昂科预计将在 2025 年下半年分享该 II 期临床试验的初步安全性和有效性结果。IMM2510/AXN-2510 是一种 PD-L1 和 VEGF 的双特异性抗体，目前正开发用于治疗多种实体肿瘤癌症","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052310244294ffd3ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052310244294ffd3ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2537977319","title":"宜明昂科-B高開近10% 預計下半年公佈IMM2510聯合化療2期試驗結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2537977319","media":"DoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537977319?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 10:00","pubTimestamp":1747965602,"startTime":"0","endTime":"0","summary":"5月23日，宜明昂科-B早盘高开近10%，现报9.99港元。公司与Instil Bio共同发布IMM2510/AXN-2510临床试验更新及非小细胞肺癌（NSCLC）开发战略。预计2025年下半年分享II期临床试验初步安全性和有效性结果，客观响应率与竞争对手类似阶段数据相当。IMM2510是一种PD-L1和VEGF双特异性抗体，用于治疗多种实体肿瘤癌症，计划年底完成一线NSCLC患者II期临床入组。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505231002209762a2ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505231002209762a2ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1176427510","title":"異動解讀 | 宜明昂科-B盤中大漲9.73%，IMM2510/AXN-2510臨牀試驗進展利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1176427510","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176427510?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 09:30","pubTimestamp":1747963830,"startTime":"0","endTime":"0","summary":"周五盘中，宜明昂科-B股价出现大幅上涨，涨幅高达9.73%，引起市场广泛关注。这一显著涨幅与公司最新发布的临床试验进展密切相关。根据公司公告，宜明昂科-B与Instil Bio, Inc.联合宣布了IMM2510/AXN-2510的临床最新情况及未来计划。IMM2510/AXN-2510是一种PD-L1和VEGF的双特异性抗体，目前正在开发用于治疗多种实体肿瘤癌症。公司预计将于今年第三季度在中国内地完成IMM2510/AXN-2510联合化疗治疗一线NSCLC患者的2期试验，约60名患者入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"1129005975","title":"異動解讀 | 宜明昂科-B盤中大漲9.73%，新藥臨牀試驗進展良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1129005975","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129005975?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 09:30","pubTimestamp":1747963830,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中大涨9.73%，引起投资者广泛关注。该股价的强劲表现与公司最新发布的临床试验进展密切相关。IMM2510/AXN-2510是一种创新型PD-L1和VEGF的双特异性抗体，目前正在开发用于治疗多种实体肿瘤癌症。该药物的3期试验预计将于明年年中在中国内地启动，目前正在与监管部门进行商讨。这一系列积极的临床进展表明，宜明昂科-B在肿瘤治疗领域的研发实力正在不断提升，有望在未来为公司带来可观的市场机遇。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 宜明昂科-B盘中大涨9.73%，新药临床试验进展良好","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"2537397174","title":"港股異動 | 宜明昂科-B(01541)高開近10% IMM2510聯合化療2期試驗結果預計下半年公佈","url":"https://stock-news.laohu8.com/highlight/detail?id=2537397174","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537397174?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 09:27","pubTimestamp":1747963648,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B高开近10%，截至发稿，涨9.73%，报10.6港元，成交额351.28万港元。消息面上，5月22日，宜明昂科和 Instil Bio, Inc.共同发布IMM2510/AXN-2510临床试验更新以及非小细胞肺癌临床开发战略。宜明昂科预计将于2025年年底完成IMM2510联合化疗治疗一线非小细胞肺癌患者的II期临床试验入组，第三季度完成约60名患者入组工作。宜明昂科预计将在2025年下半年分享该II期临床试验的初步安全性和有效性结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1296697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":191,"code":"91000000","status":"200"}]}}